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Abstract
Background: HIF-1alpha and CAIX proteins are commonly expressed under hypoxic conditions, but other
regulatory factors have been described as well. Pancreatic ductal adenocarcinoma (PDAC) is characterized
by hypoxia and strong stromal reaction and has a dismal prognosis with the currently available treatment
modalities.
Methods: We investigated the expression and prognostic role of HIF-1alpha and CAIX in PDAC series from
Northern Finland (n = 69) using immunohistochemistry.
Results: In our PDAC cases, 95 and 85% showed HIF-1alpha and CAIX expression, respectively. Low HIF-1alpha
expression correlated with poor prognosis, and multivariate analysis identified weak HIF-1alpha intensity as an
independent prognostic factor for PDAC-specific deaths (HR 2.176, 95% CI 1.216–3.893; p = 0.009). There was no
correlation between HIF-1alpha and CAIX expression levels, and the latter did not relate with survival.
Conclusions: Our findings are in contrast with previous research by finding an association between low HIF-1alpha
and poor prognosis. The biological mechanisms remain speculative, but such an unexpected relation with prognosis
and absence of correlation between HIF-1alpha and CAIX suggests that the prognostic association of HIF-1alpha may
not directly be linked with hypoxia. Accordingly, the role of HIF-1alpha might be more complex than previously
thought and the use of this marker as a hypoxia-related prognostic factor should be addressed with caution.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the
deadliest cancers worldwide [1]. Surgical and oncological
treatment of PDAC is arduous for the patient but still,
the long-term survival rates are low [2]. Surgical resec-
tion [3], often in combination with adjuvant chemother-
apy [4], is the only curative treatment of PDAC.
PDAC is characterized by hypoxia and neovasculariza-
tion [5, 6]. Hypoxia-inducible factor 1 alpha (HIF-1al-
pha) is a protein expressed under hypoxic conditions [7].
HIF-1alpha regulates tumor angiogenesis [8], and high
level of HIF-1alpha has been linked to tumor neoangio-
genesis in PDAC [9–13]. Previous studies have indicated
that strong HIF-1alpha expression associates with poor
overall survival of patients with PDAC [9, 14–20]. Car-
bonic anhydrase 9 (CAIX) is a membrane-associated
protein that is regulated by HIF-1alpha under hypoxic
conditions [21]. Increased expression has been found in
PDAC [22], and an association between abundance of
CAIX and poor prognosis has been suggested [23].
The aim of the present study was to investigate the ex-
pression of and association between HIF-1alpha and
CAIX expression and prognosis in a Finnish PDAC
cohort.* Correspondence: joni.leppanen@oulu.fi
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Methods
Patients
Some 69 patients underwent surgery for PDAC in Oulu
University Hospital during 1993–2011. For these pa-
tients, archival paraffinized specimens were collected
from the pathology archive of the hospital. Clinical data
was extracted from the patient records (Table 1). Statis-
tics Finland provided complete survival data until the
end of 2015. An expert gastrointestinal pathologist
(TJK) confirmed the PDAC diagnosis. The majority of
the patients underwent pancreaticoduodenectomy (i.e.,
Whipple procedure; n = 56) while two patients had dis-
tal pancreatectomy and 11 patients had total pancrea-
tectomy. Macroscopic venous invasion was observed in
six of the patients during the operation. Tumor grade
was not determinable in 16 patients. Patients had a me-
dian age of 66 years at diagnosis, the range being 36–
77 years. The median follow-up time in the cohort was
21 months (range 1–173 months). Of the 69 patients,
12 (17%) developed distant metastasis within 6 months
of surgery, but stage at the time of surgery was used in
the analyses. Samples of ischemic colon (n = 4) were
used as a positive control for HIF-1alpha. The study
was approved by the Oulu University Hospital Ethics
Committee (EETTMK:81/2008) and by the National
Authority for Medicolegal Affairs (VALVIRA).
Immunohistochemistry
Immunohistochemistry was performed on representa-
tive tissue block sections, chosen using hematoxylin
and eosin stainings. Commercial monoclonal mouse
antibody against HIF-1alpha (NB100-105 IgG2b, Clone
H1alpha67, Novus Biologicals, Littleton, CO) has previ-
ously been validated for use in formalin-fixed
paraffin-embedded material [24–26] and was used at a
dilution of 1:300. Dako Envision flex kit (Dako,
Copenhagen, Denmark) with high-temperature antigen
retrieval in Tris-EDTA buffer for 20 min (pH 9.0) was
used for detection of antibody reaction and diamino-
benzidine (Dako basic DAB-kit) as a chromogen. Dako
Autostainer (Dako) was used for the stainings.
The previously described monoclonal antibody M75
was used to recognize the N-terminal domain of human
CAIX [27], with normal rabbit serum acting as negative
control. Immunohistochemical staining was performed
using automated Lab Vision Autostainer 480 (Immuno-
Vision Technologies Co., Brisbane, CA) and
polymer-based Power Vision+™ Poly-HRP IHC Kit re-
agents (ImmunoVision Technologies, Co.) in room
temperature, as described earlier [28].
Three series of controls (primary antibody omitted,
primary antibody replaced with mouse primary anti-
body isotype control, and staining with irrelevant
CD3-antibody) were performed. Specimens of ischemic
intestine were used as positive controls for HIF-1alpha
staining.
Histological analysis
Two (HIF-1alpha) or three investigators (CAIX), blinded
to outcomes, evaluated the specimens as previously de-
scribed [29, 30]. HIF-1alpha (n = 64) and CAIX (n = 65)
stainings of PDAC could be evaluated due to availability
Table 1 Baseline characteristics of 69 patients with resected
pancreatic ductal adenocarcinoma
Patient clinical data n/N Percent
Age at diagnosis
< 65 34/69 49
≥ 65 35/69 51
Sex
Male 36/69 52
Female 33/69 48
Tumor size (mm)
< 30 23/69 33
30–40 31/69 45.0
> 40 15/69 22
Tumor stage
I 18/68 26
II 44/68 65
III–IV 6/68 9
Lymph nodes*
Negative 34/68 50
Positive 34/68 50
HIF-1alpha
Strong 28/64 44
Weak 36/64 56
BMI**
< 25 19/46 41
> 25 27/46 59
Smoking
Smoker** 14/33 42
Ex-smoker 7/33 21
Non-smoker 12/33 36
Alcohol usage**
Heavy 7/24 29
Moderate-No 17/24 71
Chronic pancreatitis***
Present 39/69 57
Absent 30/69 43
*Lymph node status and tumor stage were available from 68 patients
**BMI was missing from 22, smoking status from 36 patients, and alcohol
usage from 45 patients
***Present or absent chronic pancreatitis reported pre-operatively in the
patient records or in the histological analysis
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of tissue section material. Separate assessment of adja-
cent normal pancreas was conducted, including normal
duct epithelium and exocrine parenchyma (n = 35 and
n = 39 for HIF-1alpha and CAIX, respectively). Separate
assessment of membranous, cytoplasmic, and nuclear
staining in the tumor cells was conducted with scoring
of intensity on a four-point scales 0–3 (absent to strong).
For statistical analysis, nuclear HIF-1alpha intensity and
membranous CAIX intensity were divided by the median
level into two groups, weak and strong. The percentage
of positively stained cells was recorded using a five-point
scale ranging from 0 to 4: 0 = < 1%, 1 = 1–10%, 2 = 11–
49%, 3 = 50–80%, and 4 = > 80%. A score was calculated
using a formula described earlier [26]: Score = [(1 + in-
tensity)/3] × proportion of positive cells (0–4), resulting
in score ranging from 0 to 5.33. This scoring allowed the
percentage of stained cells to have greater impact on the
score than staining intensity. The median score (2.167)
was used to dichotomize the expression into two groups
(weak and strong). The mean value of the separate as-
sessments was used in the statistical analysis if the
inter-observer difference < 1 step in intensity and < 30%
in percentage. Greater discrepancies were jointly
re-evaluated, resulting in a single score. According to
these criteria, only one specimen needed re-evaluation
for CAIX intensity.
Statistical analysis
IBM SPSS statistics for Windows, version 22.0,
Armonk, NY: IBM Corp, was used for all analyses.
Nuclear HIF-1alpha and membranous CAIX intensity
between cancerous tissue and adjacent normal pan-
creatic tissue was compared with Wilcoxon paired
test. Differences between prognostic and clinicopatho-
logical variables (TNM staging, tumor grade, tumor
size, BMI, and sex) were calculated with the
chi-square test. Life tables were calculated with
Kaplan-Meier method, and survival curves compared
with log-rank test. Cox proportional hazards model
provided hazard ratios (HRs) and 95% confidence in-
tervals (CIs) for each variable. The following factors
were analyzed: nuclear HIF-1alpha staining intensity
(weak, or strong), age at diagnosis (< 65, or ≥
65 years), sex (male or female) and tumor stage (I, II,
or III–IV). Correlation between nuclear HIF-1alpha
expression and membranous CAIX expression was
obtained by Spearman’s non-parametrical correlation.
P < 0.05 was considered statistically significant.
Results
HIF-1alpha and CAIX are expressed in normal pancreas
and in pancreatic ductal adenocarcinoma
For HIF-1alpha staining, normal pancreatic tissue ad-
jacent to PDAC was present in 35/64 cases. In this
adjacent normal pancreas, there was positive nuclear
expression of HIF-1alpha in 19/35 (54%) cases and
positive cytoplasmic HIF-1alpha expression in all of
the studied cases (35/35). Nuclear and cytoplasmic
staining was present in the exocrine cells and ductal
epithelium. Positive nuclear HIF-1alpha staining was
more prevalent and extensive in cancerous tissue,
where it was found in 61/64 (95%) cases (mean pro-
portion of positive cells 37%, SD 24, range 0–95,
mean intensity 2.2, SD 0.7, range 0–3), as compared
with the adjacent normal pancreatic tissue (mean pro-
portion of positive cells 19%, SD 21, range 0–55,
mean intensity 1.1, SD 1.1, range 0–3); (p < 0.001)
(Fig. 1a, c, d).
In PDAC, cytoplasmic HIF-1alpha expression was
present in 61/64 (95%) cases (mean proportion of posi-
tive cells 82%, SD 29, range 0–100, mean intensity 1.4,
SD 0.6, range 0–3) and was more prevalent compared to
adjacent normal pancreatic tissue (mean proportion of
positive cells 95%, SD 17, range 0–100, mean intensity
1.9, SD 0.7, range 0–3); (p = 0.009) (Fig. 1a, c, d).
Co-expression of nuclear and cytoplasmic staining was
present in 60/64 cases. There was no correlation in
HIF-1alpha expression between adjacent normal pan-
creas and carcinoma cells.
In CAIX stainings, adjacent normal pancreatic tissue
was present in 39/65 cases. CAIX was expressed in nor-
mal pancreas in 27/39 (69%) cases (mean proportion
12.1%, SD 15.4, range 0–73, mean intensity 0.76, SD
0.56, range 0–2). The expression was mainly membran-
ous and located in the ductal epithelial cells. In PDCA,
CAIX was expressed in the cell membrane of the cancer
cells (Fig. 1b, e, f ), staining being present in 55/65 (85%)
cases (mean proportion 38.8%, SD 29.9, range 0–100,
mean intensity 1.65, SD 0.97, range 0–3). Membranous
CAIX staining was significantly increased in cancerous
tissue compared to adjacent normal pancreatic tissue (p
< 0.001). There was no correlation in CAIX expression
between adjacent normal pancreas and carcinoma cells.
Control stainings for HIF-1alpha
In order to confirm performance of the HIF-1alpha
staining and to exclude the possible bias caused by
unspecific positive staining, samples of ischemic colon
(n = 4) were stained with HIF-1alpha antibody for posi-
tive control. As expected, mucosal epithelium showed
positive nuclear HIF-1alpha staining in the ischemic
cells, with the staining intensity gradually increasing
from absent to strong in the cells adjacent to ischemic
necrosis (Additional file 1: Figure S1). For a negative
control PDAC, samples showing high nuclear HIF-1al-
pha were stained with CD3 antibody (n = 3). CD3 stain-
ing was present only in the lymphocytes and not in the
carcinoma cells (Additional file 1: Figure S1).
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Correlation between HIF-1alpha and CAIX
There was no correlation between nuclear or cytoplas-
mic HIF-1alpha expression intensity and membranous
CAIX intensity in carcinoma cells. No correlation was
found between HIF-1alpha and CAIX in adjacent nor-
mal pancreatic tissue. Also, no correlation in HIF-1alpha
or CAIX between adjacent normal pancreas and carcin-
oma cells was observed.
Fig. 1 HIF-1alpha and CAIX expression in PDAC and adjacent normal pancreatic tissue. Adjacent normal exocrine pancreas with weak nuclear and
cytoplasmic HIF-1alpha staining (a). Adjacent normal pancreatic tissue with weak membranous CAIX staining in the ducts and absent staining in
exocrine pancreatic tissue (b). PDAC with weak (intensity 1) nuclear and cytoplasmic HIF-1alpha staining (c). PDAC with strong (intensity 3) nuclear
and moderate (intensity 2) cytoplasmic HIF-1alpha staining (d). PDAC with weak to moderate (intensity 1–2) membranous CAIX staining (e). PDAC
with strong (intensity 3) membranous CAIX staining (f)
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Clinicopathological variables and HIF-1alpha and CAIX
expression
No correlation between nuclear HIF-1alpha expression
and clinicopathological variables (TNM stage, tumor
grade, tumor size, BMI, and sex) was found, Table 2.
Males showed a weaker membranous CAIX staining
compared to females (p = 0.038). There were no other
correlations between membranous CAIX staining and
the clinicopathological variables (Table 2).
BMI, smoking, alcohol consumption, or chronic
pancreatitis and HIF-1alpha and CAIX expression
BMI, smoking, alcohol consumption, or chronic pancrea-
titis were not associated with HIF-1alpha or CAIX expres-
sion. Chronic pancreatitis did not affect patient survival
(data not shown). Numbers and percentages of BMI,
smoking status, alcohol usage, and chronic pancreatitis are
summarized in Table 1.
Survival, HIF-1alpha and CAIX expression: univariate and
multivariate analysis
The association between HIF-1alpha and CAIX expres-
sion and 5-year survival was analyzed. Mean 5-year sur-
vival was 12 months shorter in the group with weak
nuclear HIF-1alpha intensity (21.5 months; 95% CI 15.9–
27.0) as compared with strong intensity (34.2 months;
95% CI 27.0–41.3; p = 0.007, log-rank; Fig. 2). Multivariate
analysis identified weak nuclear HIF-1alpha intensity as an
independent prognostic factor for PDAC-specific deaths
(HR 2.176, 95% CI 1.216–3.893, p = 0.009; Additional file 2:
Table S1).
Similarly, using HIF-1alpha score to address the simul-
taneous impact of the intensity and extent of the
Table 2 Intensity of HIF-1alpha and CAIX compared to clinicopathological variables in pancreatic ductal adenocarcinoma.
Statistically significant p values are italicized
Variable n/N Nuclear HIF-1alpha intensity, n n/N Membranous CAIX intensity, n
Weak Strong p Weak Strong p
pT
T1 4/64 1 3 0.439 4/65 4 0 0.533
T2 22/64 11 11 22/65 15 7
T3 32/64 20 12 33/65 23 10
T4 6/64 4 2 6/65 5 1
Lymph nodes
Positive 31/64 16 15 0.556 32/65 23 9 0.823
Negative 32/64 19 13 * 32/65 23 9 *
Stage
I 18/63 7 11 0.236 18/64 13 5 0.794
II 39/63 24 15 * 40/64 28 12 *
III–IV 6/63 4 2 6/64 5 1
Tumor grade
1 9/63 4 5 0.351 9/64 6 3 0.344
2 28/63 17 11 ** 28/64 22 6 **
3 13/63 9 4 13/64 11 2
Tumor size
> 30 mm 42/64 23 19 0.475 43/65 30 13 0.370
< 30 mm 22/64 13 9 22/65 17 5
BMI
> 25 25/43 15 10 0.366 26/44 19 7 0.186
< 25 18/43 9 9 *** 18/44 16 2 ***
Sex
Male 35/64 19 16 0.463 35/65 29 6 0.038
Female 29/64 17 12 30/65 18 12
*Lymph node status was unavailable for one patient
**Tumor grade was missing from 16 patients
***BMI was available only for 47 patients
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staining, an association between weak HIF-1alpha ex-
pression and poor survival was found. Patients with a
weak HIF-1alpha score had significantly shorter survival
time (22.5 months; 95% CI 16.3–28.6) compared to pa-
tients with a strong score (31.5 months; 95% CI 24.7–
38.2; p = 0.050). In multivariate analysis, weak
HIF-1alpha score showed an increased point estimate
for hazard ratio similar to HIF-1alpha intensity, but the
association was not statistically significant (HR 1.7,
95%CI 0.985–3.031; Additional file 3: Table S2).
CAIX expression was not associated with 5-year sur-
vival (p = 0.393). Furthermore, cytoplasmic HIF-1alpha
expression was not associated with 5-year survival
(p = 0.930).
Discussion
The results of the present study suggest that absent to
weak nuclear HIF-1alpha expression might be an inde-
pendent predictor of poor survival. No significant associ-
ation between CAIX expression and survival or the
expression levels of HIF-1 alpha and CAIX was found.
Limitations of the present study include its retrospective
nature, relatively small sample size, and low number of T4
cases in the analysis due to the inoperable nature of these
tumors (Table 2).
Several previous studies have proposed an association be-
tween strong expression of HIF-1alpha and poor prognosis
in PDAC [14]. Similarly, increased levels of CAIX in PDAC
[22, 31] and impact on poor prognosis have been suggested
[11, 23]. Although association with strong expression of
HIF-1alpha and adverse prognosis has been reported in
some other cancer types as well [32–35], there are also con-
trary reports, including association of weak HIF-1alpha ex-
pression and poor prognosis in squamous cell carcinoma of
the oral cavity [36–38] and breast cancer [39].
The mechanism linking high HIF-1alpha expression and
good prognosis remains speculative. In previous studies,
HIF-1alpha associated commonly with other hypoxia-related
markers, such as CAIX, suggesting hypoxia-dependent
HIF-1alpha expression [14]. The absence of correlation be-
tween HIF-1alpha and CAIX in PDAC cells in the present
study supports the hypothesis that rather than being regu-
lated by hypoxia, HIF-1alpha expression could be modified
by other factors. These factors include alterations in various
tumor suppressor genes and oncogenes [36, 40–45]. Previous
studies have indicated that such oxygen-independent
HIF-1alpha expression results in a diffuse expression pattern
throughout the tumor. This staining pattern is typically not
limited to ischemic areas. Such diffuse expression has been
reported in brain tumors, breast cancer, and oropharyngeal
cancers [46–49]. We hypothesize that the loss of HIF-1alpha
in tumors with adverse prognosis could just be a marker of
the simultaneous presence of multiple severe genetic aberra-
tions in PDAC cells. Furthermore, abundant expression of
HIF-1alpha and the associated good prognosis could be
manifestations of fewer genetic and functional aberrations. In
support of such interpretation, HIF-1alpha expression in the
adjacent normal pancreatic tissue was common, 54% of the
cases showing nuclear HIF-1alpha expression, and in all
cases, HIF-1alpha was detected in cytoplasm. Furthermore,
69% of the cases showed positive CAIX expression in adja-
cent normal pancreatic tissue. We hypothesize that
HIF-1alpha expression in the normal pancreatic cells indi-
cates their physiological abilities to respond to the relative
lack of oxygen. Furthermore, we suggest that HIF-1alpha ex-
pression in the cancer cells could indicate their physiological
ability to respond to hypoxia. Accordingly, high HIF-1alpha
expression in the cancer cells could be a marker of the less
malignant nature of these cells. This matter remains hypo-
thetical and further evidence to confirm the association be-
tween HIF-1alpha levels and mutations in the oncogenes
and tumor suppressor genes is needed.
In previous studies, it has been shown that oxidative
phosphorylation is associated with chemoresistance and
aggressiveness in pancreatic cancer [50]. Cells use glu-
cose in a process of glycolysis where ATP and lactate are
formed. Another mechanism involves glycolysis, which
is followed by pyruvate metabolism in the Krebs cycle
and oxidative phosphorylation in the mitochondria [51].
Oxidative phosphorylation is reduced in many cancers,
and association with poor outcome has been reported
[52]. It has been shown that pancreatic cancer is
Fig. 2 Kaplan-Meier curve visualizing the effect of weak nuclear HIF-
1alpha intensity on patient 5-year survival. Mean survival time for patients
with weak nuclear HIF-1alpha intensity (n = 36) was 21.5 months, as
patients with strong nuclear HIF-1alpha intensity (n = 28) mean survival
time was 34.2 months; (p = 0.007 log-rank)
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metabolically heterogeneous. Furthermore, the number
of tumor cells relying on oxidative phosphorylation is
high in pancreatic cancer [53]. These tumor cells are
typically highly metastatic and have more tumorigenic
potential than the cells less reliant to oxidative phos-
phorylation [54]. Furthermore, studies investigating hu-
man colon carcinoma cells in vitro have shown that
HIF-1alpha reduces oxidative phosphorylation [55]. The
HIF-1alpha expression detected in our material could be
an indicator for reduced oxidative phosphorylation and
reduced tumorigenic properties. However, this hypothet-
ical association needs to be assessed in further studies.
Methodological issues in previous studies could also
contribute to the discrepant findings about the prognostic
role of HIF-1alpha, as summarized in Table 3. Endogen-
ous biotin present in normal and neoplastic pancreas can
lead to false positive cytoplasmic or nuclear staining, thus
possibly explaining many of the previous findings [56–58].
Furthermore, the use of negative control is not reported
in all of the previous studies [14]. This, together with the
application of different antibodies and considering cyto-
plasmic staining of HIF-1alpha in the survival analysis,
could contribute to the previous discordant results
(Table 3).
Conclusion
In summary, weak nuclear HIF-1alpha expression associ-
ated with poor survival of the patients with PDAC in
our material. CAIX was overexpressed in PDAC, but did
not correlate with HIF-1alpha expression levels or prog-
nosis, suggesting that factors other than hypoxia could
also contribute to regulation of HIF-1alpha levels in
PDAC and explain the effect on survival.
Additional files
Additional file 1: Figure S1. Positive and negative controls for HIF-1alpha
staining. The HIF-1alpha staining pattern in ischemic colon sample is nuclear
and shows an increase in intensity towards the surface in the
mucosal epithelium (a.). PDAC sample with high nuclear HIF-1alpha
intensity stained with CD3 antibody for negative control (b.). CD3
staining is located in the lymphocytes but not in the cancer cells.
(TIF 5034 kb)
Additional file 2: Table S1. Multivariate analysis for the contribution of
clinical factors of pancreatic ductal adenocarcinoma to mortality after
controlling for other variables. Tested explanatory variables were nuclear
HIF-1alpha staining intensity (weak and strong), age at the time of diagnosis
(< 65 or≥ 65 years), sex (male or female) and tumor stage (I, II or III-IV).
(DOCX 14 kb)
Additional file 3: Table S2. Multivariate analysis for the contribution of
clinical factors of pancreatic ductal adenocarcinoma to mortality after
controlling for other variables. Tested explanatory variables were nuclear
HIF-1alpha score (weak and strong), age at the time of diagnosis (< 65
or ≥ 65 years), sex (male or female) and tumor stage (I, II or III-IV).
(DOCX 14 kb)
Abbreviations
CAIX: Carbonic anhydrase; HIF-1alpha: Hypoxia-inducible factor 1 alpha;
PDAC: Pancreatic ductal adenocarcinoma
Table 3 Immunohistochemical detection methods in the original articles included in the meta-analysis by Ye et al. [14]
Paper Patients
(n)
Immunohistochemistry procedures HIF-1alfa
antibody
source and
clone
Biotin
based
Prognostic effect of HIF-1alpha Reference
Sun et al.
2007
58 Supervision™, negative controls BA0912,
Wuhan Boster, China
? High nuclear and/or cytoplasmic
HIF-1alpha ➔ poor overall survival
[10]
Zhu et al.
2013
63 Supervision™, negative controls Not mentioned ? High nuclear and/or cytoplasmic
HIF-1alpha ➔ poor overall survival
[20]
Zhang
et al. 2010
65 Biotinylated goat anti-mouse or anti-
rabbit (Streptavidin/peroxidase), negative
controls
Santa Cruz, CA, USA Yes High nuclear and/or cytoplasmic
HIF-1alpha ➔ poor overall survival
[18]
Miyake
et al. 2008
39 Avidin-biotin (Dako LSAB™), no negative
controls mentioned
Novus Biologicals,
Littleton, CO
Yes High nuclear HIF-1alpha ➔ poor
overall survival
[17]
Matsuo
et al. 2014
100 Avidin-biotin, no negative controls
mentioned
Not mentioned Yes High nuclear and/or cytoplasmic
HIF-1alpha ➔ poor overall survival
[9]
Ide et al.
2007
41 Biotinylated anti-mouse, anti-rabbit anti
body conjugated to a peroxidase-labeled
dextran polymer (Dako EnVision+™), no
negative control mentioned
Clone HI-67, Novus
Biologicals, Littleton, CO
No High nuclear and/or cytoplasmic
HIF-1alpha ➔ worse disease free
survival, no correlation between
HIF-1alpha and overall survival
[16]
Spivak-
Kroizman
et al. 2013
129 Bond™ Polymer Refine Detection Kit, no
negative control mentioned
BD Biosciences No High nuclear HIF-1alpha ➔ poor
overall survival
[15]
Zhao
et al. 2012
95 Streptavidin biotin-peroxidase, biotinylated
secondary antibody, no negative control
mentioned
sc-10790, Santa Cruz,
CA, USA
Yes HIF-1alpha localization not mentioned.
High HIF-1alpha ➔ poor overall survival
[19]
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